The TCLI locus on chromosome 14q32.1 is frequently involved in chromosomal translocations and inversions with one of the T-cefl receptor loci in human T-cell leukemias and lymphomas. The chromosome 14 region translocated or rearranged involves -350 kb ofDNA at chromosome band 14q32.1. Within this region we have identified a gene coding for a 1.3-kb transcript, expressed only in restricted subsets of cells within the lymphoid lineage and expressed at high levels in leukemic cells carrying a t(14;14)(qll;q32) chromosome translocation or a inv(14)(qll;q32) chromosome inversion. The cognate cDNA sequence reveals an open reading frame of 342 nt encoding a protein of 14 kDa. The TCLI gene sequence, which, to our knowledge, shows no sequence homology with other human genes, is preferentiafly expressed early in T-and B-lymphocyte differentiation.

To determine whether the FHIT gene at 3pl4.2 is altered in head and neck squamous cell carcinomas (HNSCC), we examined 26 HNSCC cell lines for deletions within the FHIT locus by Southern analysis, for allelic losses of specific exons FHIT by fluorescence in situ hybridization (FISH) and for integrity of FHIT transcripts. Three cell lines exhibited homozygous deletions within the FHIT gene, 55% (15/25) showed the presence of aberrant transcripts, and 65% (13/20) Head and neck cancers represent 3% of all cancer in Western countries (1), and in some geographical regions such as India, the incidence is as high as 45% (2); 90-95% of these tumors are head and neck squamous cell carcinomas (HNSCC). HNSCC has a high mortality rate with a 5 year survival of 40%. Tobacco and alcohol have been recognized as etiological factors of these carcinomas, and the reported increase in the incidence of HNSCC by epidemiological studies is probably due to changes in consumption of these agents (2).Several regions of loss of heterozygosity (LOH) have been identified in HNSCC recently, including regions of 3p, 9p, llq, 13q, and 17p (3, 4). Among these loci, the 9p region presents the highest rate of genetic alteration at 75%, followed by alterations of 3p ranging between 45% and 55% (4, 5). LOH of 9p has been linked to the tumor suppressor gene, CDKN2 (6-8), whereas LOH on 3p has not yet been associated with specific genes.Deletions of the short arm of chromosome 3 are common in many human cancers, including sporadic and hereditary renal carcinomas, small-cell lung carcinomas (SCLC) (9, 10) and non-small-cell lung carcinomas (NSCLC) (11, 12) and carcinomas of the breast and cervix (13,14). In this regard, it is interesting to note that the most common fragile site in humans, FRA3B, is at 3pl4.2 (for reviews, see refs. 15 Recently, we have cloned the FHIT gene, at 3pl4.2, which encompasses the FRA3B fragile site, is disrupted by the t(3;8) chromosomal translocation observed in a family with renal cell carcinoma, and spans a region commonly deleted in cancer cell lines (20,21). We have also shown that "80% of SCLC and 40% of NSCLC express aberrant FHIT transcripts (22), suggesting that the FHIT gene is a frequent target for alteration in lung tumors. SCLC and HNSCC present the same type of histology, share major etiological factors such as tobacco (23,24), and exhibit similar regions of LOH of the short arm of chromosome 3. To determine whether the FHIT gene is also disrupted and aberrantly transcribed in HNSCCs, we studied 26 early passage HNSCC-derived cell lines. MATERIALS AND METHODS RNA Extraction and Reverse Transcription-PCR (RT-PCR). Total RNA was extracted from cell lines using RNAzol (Tel-Test, Friendswood, TX) and cDNA synthesized from 1 ,ug of total RNA. RT was performed in a 20 ,ul volume of 1 x first strand buffer (GIBCO), 10 mM DTT, 500 mM of each dNTP, 0.3 mg/ml random primers (GIBCO), and 300 units of SuperScript II (GIBCO) reverse transcriptase. The samples were first incubated 5 min at 65°C and then at 37°C ...

The TCL1 oncogene on human chromosome 14q32.1 is involved in the development of T cell leukemia in humans. These leukemias are classified either as T prolymphocytic leukemias, which occur very late in life, or as T chronic lymphocytic leukemias, which often arise in patients with ataxia telangiectasia (AT) at a young age. The TCL1 oncogene is activated in these leukemias by juxtaposition to the ␣ or ␤ locus of the T cell receptor, caused by chromosomal translocations t(14:14)(q11:q32), t(7:14)(q35:q32), or by inversions inv(14)(q11:q32). To show that transcriptional alteration of TCL1 is causally involved in the generation of T cell neoplasia we have generated transgenic mice that carry the TCL1 gene under the transcriptional control of the p56 lck promoter element. The lck-TCL1 transgenic mice developed mature T cell leukemias after a long latency period. Younger mice presented preleukemic T cell expansions expressing TCL1, and leukemias developed only at an older age. The phenotype of the murine leukemias is CD4 ؊ CD8 ؉ , in contrast to human leukemias, which are predominantly CD4 ؉ CD8؊ . These studies demonstrate that transcriptional activation of the TCL1 protooncogene can cause malignant transformation of T lymphocytes, indicating the role of TCL1 in the initiation of malignant transformation in T prolymphocytic leukemias and T chronic lymphocytic leukemias.

The signaling pathways that commit cells to migration are incompletely understood. We employed human mammary cells and two stimuli: epidermal growth factor (EGF), which induced cellular migration, and serum factors, which stimulated cell growth. In addition to strong activation of ERK by EGF, and AKT by serum, early transcription remarkably differed: while EGF induced early growth response-1 (EGR1), and this was required for migration, serum induced c-Fos and FosB to enhance proliferation. We demonstrate that induction of EGR1 involves ERK-mediated down-regulation of microRNA-191 and phosphorylation of the ETS2 repressor factor (ERF) repressor, which subsequently leaves the nucleus. Unexpectedly, knockdown of ERF inhibited migration, which implies migratory roles for exported ERF molecules. On the other hand, chromatin immunoprecipitation identified a subset of direct EGR1 targets, including EGR1 autostimulation and SERPINB2, whose transcription is essential for EGF-induced cell migration. In summary, EGR1 and the EGF-ERK-ERF axis emerge from our study as major drivers of growth factor-induced mammary cell migration.